Knoa Pharma was founded to help abate the opioid crisis. That public health purpose drives everything we do.
Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health.
We expand access to lifesaving overdose reversal medicines and deliver affordable treatments for opioid use disorder, while ensuring the safe and responsible distribution of medicines that are critical to patient care, including opioid analgesics. We also innovate to address unmet patient needs and enhance our robust generics portfolio.
Owned by a not-for-profit foundation, every aspect of the business is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference.
We are guided by a public health purpose and operate with transparency and accountability to the public.
The Company will showcase its investigational pipeline assets and invite conversations with potential partners at the Congress, September 23-24, in Boston.
Stamford, Conn., July 1, 2026 – Knoa Pharma today announced the appointment of Michael Goettler as President and Chief Executive Officer, effective July 6.
Please read carefully the Knoa Pharma LLC Privacy Policy (the “Privacy Policy”), which is part of the Knoa Pharma LLC Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through your use of the Service, how we use it, how we share it, how we protect it, and the choices you can make about your information.
